-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
EXCLUSIVE: Psyched Wellness CEO Breaks Down Mushroom Strategy, From 'Alice In Wonderland' To The Checkout Aisle
EXCLUSIVE: Psyched Wellness CEO Breaks Down Mushroom Strategy, From 'Alice In Wonderland' To The Checkout Aisle
Psyched Wellness Ltd (OTCQB:PSYCF) plans to begin selling a psychoactive mushroom extract this summer that's never been scheduled as a drug in the U.S.
It's derived from amanita muscaria, an instantly recognizable, red-capped fungi, and its active ingredient muscimol.
"Everyone knows what this mushroom is by sight. You've seen 'Alice in Wonderland.' You've seen it on your phone. It's the mushroom emoji," Psyched Wellness CEO Jeffrey Stevens told the inaugural Benzinga Psychedelics Capital Conference Tuesday in Miami Beach.
Here's what psychedelics investors need to know.
The Product: Psyched's first product, a tincture named Calm, will be sold in the U.S. as a food supplement and is intended as a sleep aid.
It's built on Psyched's proprietary amanita muscaria extract AME-1. The extraction is key: the reason the mushroom never caught on from a recreational standpoint is that it would make you ill to eat it without any extraction process, the CEO said.
"You can't put any patents on a mushroom, but you certainly can on the processes," Stevens said.
Long used by indigenous groups, muscimol acts on the GABAA receptors and is a powerful compound, he said.
"The regulatory landscape for this mushroom is quite unique," Stevens said, adding that it can be sold over the counter.
What's Next For Psyched Wellness: The distribution strategy for Psyched's first-to-market product Calm targets over 200,000 retail outlets, said CCO Matthew Singh.
The company is developing beverage, pain management, anti-inflammatory, beauty and cosmetic products, slow-release capsules, a tea steeping bag and topical creams for future release, said Singh, who previously worked with Coca-Cola Co (NYSE:KO), Red Bull and Vital Pharmaceuticals.
Psyched is planning a commercial vertical with wholesale white label and private label applications of the AME-1 extract, he said.
"We have a wide assortment of what we want to do with this mushroom and its incredible healing power."
Psyched Wellness Ltd (OTCQB:PSYCF) plans to begin selling a psychoactive mushroom extract this summer that's never been scheduled as a drug in the U.S.
心智健康有限公司(場外交易代碼:PSYCF)計劃今年夏天開始銷售一種具有精神活性的蘑菇提取物,這種提取物在美國從未被列為藥物。
It's derived from amanita muscaria, an instantly recognizable, red-capped fungi, and its active ingredient muscimol.
它來自毒蛾,一種一眼就能辨認出來的紅帽真菌,及其活性成分麝香酚。
"Everyone knows what this mushroom is by sight. You've seen 'Alice in Wonderland.' You've seen it on your phone. It's the mushroom emoji," Psyched Wellness CEO Jeffrey Stevens told the inaugural Benzinga Psychedelics Capital Conference Tuesday in Miami Beach.
“每個人都一眼就知道這個蘑菇是什麼。你看過《愛麗絲夢遊仙境》。你在手機上看到過它。這是蘑菇表情符號,”心理健康首席執行官説傑弗裏·史蒂文斯週二在邁阿密海灘舉行的首屆Benzinga迷幻資本會議上説。
Here's what psychedelics investors need to know.
以下是迷幻藥投資者需要知道的事情。
The Product: Psyched's first product, a tincture named Calm, will be sold in the U.S. as a food supplement and is intended as a sleep aid.
產品:安琪的第一款產品是一種名為Calm的藥酒,將作為食品補充劑在美國銷售,旨在幫助睡眠。
It's built on Psyched's proprietary amanita muscaria extract AME-1. The extraction is key: the reason the mushroom never caught on from a recreational standpoint is that it would make you ill to eat it without any extraction process, the CEO said.
它是建立在安琪專有的鵝膏菌提取物AME-1上的。提取是關鍵:從娛樂的角度來看,蘑菇從未流行起來的原因是,不經過任何提取過程就吃了它會讓你生病,這位首席執行官説。
"You can't put any patents on a mushroom, but you certainly can on the processes," Stevens said.
史蒂文斯説:“你不能為蘑菇申請任何專利,但你當然可以為其工藝申請專利。”
Long used by indigenous groups, muscimol acts on the GABAA receptors and is a powerful compound, he said.
他説,麝香酚長期被土著羣體使用,作用於GABAA受體,是一種強大的化合物。
"The regulatory landscape for this mushroom is quite unique," Stevens said, adding that it can be sold over the counter.
“這種蘑菇的監管環境是非常獨特的,”史蒂文斯説,並補充説,它可以在櫃枱銷售。
What's Next For Psyched Wellness: The distribution strategy for Psyched's first-to-market product Calm targets over 200,000 retail outlets, said CCO Matthew Singh.
心理健康的下一步是什麼:CCO表示,Pecked的首個上市產品Calm的分銷戰略瞄準了20多萬家零售店馬修·辛格.
The company is developing beverage, pain management, anti-inflammatory, beauty and cosmetic products, slow-release capsules, a tea steeping bag and topical creams for future release, said Singh, who previously worked with Coca-Cola Co (NYSE:KO), Red Bull and Vital Pharmaceuticals.
辛格説,該公司正在開發飲料、止痛、消炎、美容和美容產品、緩釋膠囊、浸茶袋和局部霜,以供未來發布可口可樂公司(紐約證券交易所代碼:KO)、紅牛和VITAL製藥。
Psyched is planning a commercial vertical with wholesale white label and private label applications of the AME-1 extract, he said.
他説,Enched正在計劃一個商業垂直領域,批發白色標籤和AME-1提取物的私人標籤應用。
"We have a wide assortment of what we want to do with this mushroom and its incredible healing power."
“我們有各種各樣的想法來處理這種蘑菇及其不可思議的治癒能力。”
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧